WEBULL
News
ACRS
3.690
+3.36%
0.120
Weekly Report: what happened at ACRS last week (0202-0206)?
Weekly Report · 1d ago
Aclaris Therapeutics nimmt an zwei Healthcare-Konferenzen teil
Reuters · 5d ago
Aclaris Therapeutics to Present at Major Healthcare Conferences
Reuters · 5d ago
There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump
Simply Wall St · 02/03 11:16
Weekly Report: what happened at ACRS last week (0126-0130)?
Weekly Report · 02/02 09:07
Aclaris Therapeutics initiated with a Buy at Craig-Hallum
TipRanks · 01/30 12:11
Craig-Hallum bullish on Aclaris Therapeutics, initiates with a Buy
TipRanks · 01/30 12:10
Looking Into Aclaris Therapeutics Inc's Recent Short Interest
Benzinga · 01/29 13:00
Analysts’ Top Healthcare Picks: Aclaris Therapeutics (ACRS), Inventiva (IVA)
TipRanks · 01/28 11:30
Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug
Benzinga · 01/27 18:12
Aclaris Therapeutics’ ATI-2138 Shows Superior Hair Regrowth in Severe Alopecia Areata Preclinical Study
Reuters · 01/27 15:01
Aclaris Therapeutics reports ‘positive’ results from ATI-2138
TipRanks · 01/27 12:01
Aclaris Therapeutics Announces Preclinical Results From Potent And Selective ITK/JAK3 Inhibitor ATI-2138 In Murine Model Of Severe Alopecia Areata
Benzinga · 01/27 11:56
ACLARIS THERAPEUTICS INC - TO INITIATE PHASE 2B TRIAL FOR ATI-2138 IN FIRST HALF OF 2026
Reuters · 01/27 11:55
Aclaris Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since January 2024 -- Data Talk
Dow Jones · 01/26 19:29
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress, up 72% over last week
Simply Wall St · 01/26 10:10
Weekly Report: what happened at ACRS last week (0119-0123)?
Weekly Report · 01/26 09:07
Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Dow Jones · 01/21 11:38
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Tvardi Therapeutics (TVRD)
TipRanks · 01/21 11:30
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target
Benzinga · 01/21 11:28
More
Webull provides a variety of real-time ACRS stock news. You can receive the latest news about Aclaris Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).